- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00770692
A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150)
A Phase III Study of SEP-190 (Eszopiclone) in Patients With Insomnia
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Akita, Japan
-
Fukuoka, Japan
-
Kochi, Japan
-
Kumamoto, Japan
-
Kyoto, Japan
-
Osaka, Japan
-
-
Aichi
-
Nagoya, Aichi, Japan
-
-
Fukuoka
-
Iizuka, Fukuoka, Japan
-
Kitakyushu, Fukuoka, Japan
-
Kurume, Fukuoka, Japan
-
Onga, Fukuoka, Japan
-
-
Gunma
-
Maebashi, Gunma, Japan
-
-
Hokkaido
-
Sapporo, Hokkaido, Japan
-
-
Hyogo
-
Itami, Hyogo, Japan
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan
-
Yokoyama, Kanagawa, Japan
-
-
Nara
-
Kashiba, Nara, Japan
-
-
Okinawa
-
Urazoe, Okinawa, Japan
-
-
Osaka
-
Ibaragi, Osaka, Japan
-
Kishiwada, Osaka, Japan
-
-
Saitama
-
Fujimi, Saitama, Japan
-
-
Shiga
-
Kusatsu, Shiga, Japan
-
-
Tokyo
-
Arakawa-ku, Tokyo, Japan
-
Chuo-ku, Tokyo, Japan
-
Edogawa-ku, Tokyo, Japan
-
Kodaira, Tokyo, Japan
-
Koto-ku, Tokyo, Japan
-
Minato-ku, Tokyo, Japan
-
Musashino, Tokyo, Japan
-
Ota-ku, Tokyo, Japan
-
Shinagawa-ku, Tokyo, Japan
-
Shinjuku-ku, Tokyo, Japan
-
Toshima-ku, Tokyo, Japan
-
-
Yokohama
-
Sagamihara, Yokohama, Japan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Participants who submit written informed consent for study entry.
- Participants aged greater than or equal to 20 and less than 85 years of age at the time of obtaining informed consent.
- Participants diagnosed with primary insomnia based on the Diagnostic and Statistical Manual of Mental Disorders, text revision (DSM-IV-TR) Japanese version or diagnosed with insomnia associated with psychiatric or physical disorder(s).
Participants with both of the following conditions which are persistent for 4 weeks or longer before the start of observation period:
- Total sleep time is less than or equal to 390 minutes for more than or equal to 3 days a week
- Time to fall asleep taking more than or equal to 30 minutes for more than or equal to 3 days a week
Participants with data at least 2 consecutive days in diary entries during observation period and confirmed to meet the following two criteria:
- Total sleep time of less than or equal to 390 minutes for more than or equal to 3 days a week
- Time to fall asleep taking more than or equal to 30 minutes for more than or equal to 3 days a week
Exclusion criteria:
Participants with a present or history of the following disease specified in
Mini-International Neuropsychiatric Interview (M.I.N.I.) Japanese version 5.0:
- Risk of suicide
- (Mild) manic episode
- Post-traumatic stress disorder (PTSD)
- Alcohol dependence and abuse
- Drug (non-alcohol) dependence and abuse
- Anorexia nervosa
- Bulimia nervosa
- Anti-social personality disorder
- Participants with pharmacologically induced insomnia (drug-induced insomnia).
- Participants with comorbid primary sleep disorders (circadian rhythm disorder, restless legs movement syndrome, periodic limb movement disorder, sleep apnea syndrome, etc.) other than primary insomnia.
- Participants with symptoms that significantly disturb sleep such as pain, fever, diarrhea, frequent micturation, and cough.
- Participants with unstable primary disease presenting insomnia during 4 weeks before the start of observation period.
- Participants with organic mental disorder.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Eszopiclone 1 mg- Elderly
|
Elderly participants: Eszopiclone 1 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks. Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment.
Other Names:
|
EXPERIMENTAL: Eszopiclone 2 mg- Elderly
|
Elderly participants: Eszopiclone 2 mg tablet and 1 tablet placebo 1 mg daily by mouth at bedtime for 24 weeks. Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment.
Other Names:
|
EXPERIMENTAL: Eszopiclone 2 mg- Non-elderly
|
Non-elderly participants: Eszopiclone 2 mg tablet and 1 tablet of placebo 3 mg daily by mouth at bedtime for 24 weeks. Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment.
Other Names:
|
EXPERIMENTAL: Eszopiclone 3 mg- Non-elderly
|
Non-elderly participants: Eszopiclone 3 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks. Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse Events
Time Frame: Up to 25 weeks (24 weeks treatment period & 1 week follow-up)
|
Incidence of adverse events was defined as: (number of participants with adverse events/ number of participants analyzed in the safety analysis set)*100. An adverse event was defined as any unwanted or untoward disease or its symptom, sign, or abnormality in laboratory parameters in a subject who receives a study drug. An adverse event does not necessarily have a causal relationship with the study drug. The investigator or subinvestigator evaluated adverse events and recorded the results in the case report form (CRF). The investigator or subinvestigator recorded all adverse events occurring after the start of study treatment in the CRF, irrespective of the causal relationship with the study drug or the study procedures. All data collected from the follow-up was recorded in CRF. |
Up to 25 weeks (24 weeks treatment period & 1 week follow-up)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change From Baseline In Sleep Latency
Time Frame: Baseline (screening period) and 4 weeks of treatment
|
Based on subjective symptoms, the participants recorded their sleep latency (the amount of time measured in minutes it takes to fall asleep) in a sleep diary questionnaire for the week preceding the start of the study treatment (the day on which the patient was enrolled in the treatment period), as well as between the day on which the study treatment started and the Week 4 visit.
For pre-treatment (screening period), the representative value was calculated from the data of the 7 days preceding enrollment in the treatment period.
A median of all the data between the day of enrollment in the treatment period and the day before dose escalation judgment was presented as the data of the overall period.
The change was calculated as the sleep latency of the overall period assessment - sleep latency at baseline (screening period).
|
Baseline (screening period) and 4 weeks of treatment
|
Mean Change From Baseline in Wake Time After Sleep Onset (WASO)
Time Frame: Baseline (screening period) and 4 weeks of treatment
|
Based on subjective symptoms, the participants recorded their WASO defined as total awakening time from falling asleep to final awakening in a sleep diary questionnaire for the week preceding the start of the study treatment (the day on which the patient was enrolled in the treatment period), as well as between the day on which the study treatment started and the Week 4 visit.
For pre-treatment (screening period), the representative value was calculated from the data of the 7 days preceding enrollment in the treatment period.
A median of all the data between the day of enrollment in the treatment period and the day before dose escalation judgment was presented as the data of the overall period.
The change was calculated as the WASO of the overall period assessment - WASO at baseline (screening period).
|
Baseline (screening period) and 4 weeks of treatment
|
Mean Change From Baseline in Total Sleep Time
Time Frame: Baseline (screening period) and 4 weeks of treatment
|
Based on subjective symptoms, the participants recorded their total sleep time defined as total sleeping time from bedtime to final awakening in a sleep diary questionnaire for the week preceding the start of the study treatment (the day on which the patient was enrolled in the treatment period), as well as between the day on which the study treatment started and the Week 4 visit.
For pre-treatment (screening period), the representative value was calculated from the data of the 7 days preceding enrollment in the treatment period.
A median of all the data between the day of enrollment in the treatment period and the day before dose escalation judgment was presented as the data of the overall period.
The change was calculated as the total sleep time of the overall period assessment - total sleep time at baseline (screening period).
|
Baseline (screening period) and 4 weeks of treatment
|
Mean Change From Baseline in Total Number of Awakenings
Time Frame: Baseline (screening period) and 4 weeks of treatment
|
Based on subjective symptoms, the participants recorded their number of awakenings defined as total number of spontaneous awakenings from falling asleep to final awakening in a sleep diary questionnaire for the week preceding the start of the study treatment (the day on which the patient was enrolled in the treatment period), as well as between the day on which the study treatment started and the Week 4 visit.
For pre-treatment (screening period), the representative value was calculated from the data of the 7 days preceding enrollment in the treatment period.
A median of all the data between the day of enrollment in the treatment period and the day before dose escalation judgment was presented as the data of the overall period.
The change was calculated as the total number of awakenings of the overall period assessment - total number of awakenings at baseline (screening period).
|
Baseline (screening period) and 4 weeks of treatment
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 190-150
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insomnia
-
National Yang Ming UniversityBened Biomedical Co., Ltd.Not yet recruiting
-
Leiden University Medical CenterNot yet recruiting
-
Weill Medical College of Cornell UniversityMARPACCompleted
-
Regenstrief Institute, Inc.Merck Sharp & Dohme LLC; National Sleep FoundationUnknownInsomniaUnited States
-
Posit Science CorporationUniversity of California, San FranciscoCompleted
-
University of UtahNational Center for Complementary and Integrative Health (NCCIH)Completed
-
Minneapolis Veterans Affairs Medical CenterWithdrawn
-
GlaxoSmithKlineWithdrawn
-
Coeruleus Ltd.Completed
-
PfizerCompleted
Clinical Trials on Eszopiclone 1 mg- Elderly
-
Eisai Co., Ltd.Completed
-
Eisai Co., Ltd.Completed
-
University of California, San DiegoAmerican Academy of Sleep MedicineRecruitingObstructive Sleep ApneaUnited States
-
SunovionCompleted
-
Laboratorios Andromaco S.A.Completed
-
University of Sao Paulo General HospitalRecruitingInsomnia | Obstructive Sleep ApneaBrazil
-
Dr. Reddy's Laboratories LimitedCompleted
-
University of Medicine and Dentistry of New JerseySunovionCompletedParkinson's Disease | InsomniaUnited States
-
Dr. Reddy's Laboratories LimitedCompleted
-
University of PittsburghSunovion; American Academy of Sleep MedicineCompletedSleep Initiation and Maintenance Disorders | Primary InsomniaUnited States